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Immunoglobulins are unique molecules capable of simultaneously recognizing a diverse
array of antigens and themselves being recognized by a broad array of receptors. The
abundance specifically of the IgG subclass and the variety of signaling receptors to which
it binds render this an important immunomodulatory molecule. In addition to the clas-
sical Fcγ receptors that bind IgG at the cell surface, the neonatal Fc receptor (FcRn)
is a lifelong resident of the endolysosomal system of most hematopoietic cells where
it determines the intracellular fate of both IgG and IgG-containing immune complexes
(IgG IC). Cross-linking of FcRn by multivalent IgG IC within antigen presenting cells such
as dendritic cells initiates specific mechanisms that result in trafficking of the antigen-
bearing IgG IC into compartments from which the antigen can successfully be processed
into peptide epitopes compatible with loading onto both major histocompatibility com-
plex class I and II molecules. In turn, this enables the synchronous activation of both
CD4+ and CD8+ T cell responses against the cognate antigen, thereby bridging the gap
between the humoral and cellular branches of the adaptive immune response. Critically,
FcRn-driven T cell priming is efficient at very low doses of antigen due to the exquis-
ite sensitivity of the IgG-mediated antigen delivery system through which it operates.
FcRn-mediated antigen presentation has important consequences in tissue compartments
replete with IgG and serves not only to determine homeostatic immune activation at a
variety of sites but also to induce inflammatory responses upon exposure to antigens
perceived as foreign. Therapeutically targeting the pathway by which FcRn enables T
cell activation in response to IgG IC is thus a highly attractive prospect not only for the
treatment of diseases that are driven by immune complexes but also for manipulating
local immune responses against defined antigens such as those present during infections
and cancer.
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INTRODUCTION
Coordination of immune responses is of key importance to
the maintenance of homeostasis within multicellular organisms.
Fundamental to this process is the recognition, processing, and
presentation of antigenic agents that allows integration of the var-
ious branches of the innate and adaptive immune systems that
cooperate to confer maximal protective immunity. Antigen detec-
tion, which serves as the initiating event in this cascade, occurs
via numerous mechanisms having varying levels of sensitivity and
specificity. How an antigen is detected depends at once on the
nature of the antigen itself as well as on the particular immune
cell that detects it. Whereas small soluble antigens can be taken up
passively via macropinocytosis or fluid phase endocytosis, larger
antigens require processes such as phagocytosis for cellular entry.
Specificity for antigen detection, uptake, and/or processing is con-
ferred by cellular receptors that may bind to a unique ligand,
such as insulin-like growth factor receptor 1 (IGFR1), or to a
conserved motif present on many ligands, such as the mannose
receptor (MR) DC-SIGN. In each case, ligand binding by the
receptor can not only initiate ligand internalization but also trigger
additional signaling cascades, which exert direct or indirect effects
on subsequent antigen presentation.
Recognition of IgG by Fcγ receptors (FcγRs) represents an
important strategy that enables the delivery of unique antigenic
determinants in the form of an IgG immune complex (IgG IC) via
binding of the conserved Fc receptor (FcRn) domains on IgG to
their receptor. In antigen presenting cells (APCs), this process is
initiated at the cell surface by FcγR ligation, which triggers both
the internalization of IgG and its delivery into endocytic vesicles.
Importantly, while monomeric IgG is efficiently recycled from
these compartments to the cell surface, antigen-containing IgG
immune complexes (IgG IC) are instead trafficked into vesicles
where processing of the complexed antigen releases epitopes that
are loaded onto MHC class I (MHC-I) and class II (MHC-II) mol-
ecules that subsequently stimulate the activation of cognate CD8+
and CD4+ T cells. Importantly, following entry into the cell, rout-
ing of the IgG or IgG IC through the maze of acidic endocytic
compartments is mediated neither by FcγR nor by non-specific
distributive mechanisms but rather by the specific binding of IgG
to its intracellular receptor, the neonatal Fc receptor (FcRn).
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Best known for its roles in protecting circulating IgG from
catabolism and mediating IgG transcytosis across polarized
epithelial cells at mucosal surfaces, FcRn also plays a critical role in
the immune system. Lifelong, high level expression of FcRn in APC
such as dendritic cells (DC), macrophages, and B cells enables the
specific intracellular trafficking of IgG and antigen-containing IgG
IC through the endolysosomal system. Importantly, in the case of
the latter, this mechanism results in the delivery of complexed anti-
gen into compartments in which the local degradative conditions
favor epitope conservation and the loading of immunostimulatory
antigenic epitopes onto MHC-I and MHC-II. FcRn expression
within APC thus has important immunological consequences for
the generation of targeted T cell mediated immunity following the
triggering of a generic cellular entry pathway by the conserved Fc
portion of IgG. Rather uniquely, FcRn-mediated activation of T
cells in response to IgG IC serves to integrate the humoral and cell-
mediated branches of the adaptive immune system and to coor-
dinate the innate immune system, thereby promoting maximal
protective immunity.
ANTIGEN PRESENTATION
MHC CLASS I AND II PEPTIDE LOADING
Functionally, antigen presentation has evolved as a mechanism by
which T cells can monitor the antigenic composition of the body
for the presence of potential pathogens. Given the immense vari-
ability in antigen structure and composition, the development of a
systematized way for T cells to rapidly and efficiently monitor anti-
genic diversity in their environment can be considered essential
for maximizing organism survival. The major histocompatibility
complex (MHC) molecules, which are expressed at the cell sur-
face in complex with antigenic epitopes, present the T cell with a
conserved recognition structure, the MHC molecule itself, in con-
junction with a unique peptide that transmits information about
the antigenic milieu. Collectively, T cells are thus able to monitor
an immense array of antigens due to a multitude of clonotypically
expressed T cell receptors (TCR).
The peptide binding characteristics differ among different
classes of MHC molecules. MHC-I molecules, which are rec-
ognized by CD8+ T cells, bind peptides of 8–11 amino acids
in length that are generated largely via the process of pro-
teasomal degradation in the cytosol (1). Peptide loading onto
MHC-I occurs in the endoplasmic reticulum (ER) after cyto-
plasmic proteasomal digestion and subsequent peptide import by
the transporter associated with antigen processing (TAP) across
the ER membrane. The vast majority of peptides presented by
MHC-I are thus endogenous to the cell itself (1, 2). In special-
ized cell types, particularly DC, exogenously acquired antigens
can be presented by MHC-I through a process known as cross-
presentation as discussed further below (3). MHC-II molecules,
which educate or activate CD4+ T cells in the thymus or periph-
ery, respectively, bind peptides of 10–30 amino acids in length,
which are typically exogenously derived and processed by lyso-
somal proteolysis. While most cells engage in MHC-I presenta-
tion, APCs are proficient at both MHC-I and MHC-II presen-
tation due to the specialized intracellular machinery that they
possess.
PROCESSING PATHWAYS FOR EXOGENOUS ANTIGENS
The generation of peptides suitable for loading onto MHC mole-
cules is dictated at once by the nature of the antigen, the route of
uptake, and additional signals to which the cell is exposed. With
respect to the contribution of the antigen itself, certain epitopes of
a protein often exhibit immunodominance leading to the preferen-
tial processing and presentation of such epitopes over others (4, 5).
Many factors contribute to the preferential selection of certain epi-
topes, including the activation state of the APC, the relative protein
abundance, the availability and activity of enzymes responsible for
antigen processing, and previous antigen exposure. Importantly,
immunodominance can have profound implications not only for
shaping the immediate direction of an immune response but also
the nature of future immune response by altering memory T cell
pools (1, 4).
Processing of exogenous antigen for loading onto MHC-II mol-
ecules is initiated upon entry into the early endosome. As the
antigen moves progressively deeper into the endolysosomal sys-
tem, the pH of the vesicles progressively decreases from the mildly
acidic environment of the early endosome to the highly acidic
milieu of the lysosome (6). Degradation of the antigen occurs
largely by the actions of various enzymes, particularly cathepsin
proteases and the γ-interferon-inducible lysosomal thiolreductase
(GILT), whose activity is regulated by the local pH (7). While there
is considerable heterogeneity in the morphology and content of
the various endolysosomal compartments and MHC-II molecules
can be found throughout compartments at various stages of mat-
uration, the majority of evidence indicates that epitope loading
onto MHC-II occurs in the late endosome, which has also been
referred to as an MHC-II compartment, where numerous chap-
erones facilitate this process (8). However, conditions within both
the late endosome and phagosome are thought to be optimal for
the generation of peptides ideal for MHC-II loading and traffick-
ing of such peptides between these two compartments is known to
occur (1, 2). Given the dependence of antigenic processing on pH,
the efficiency of productive antigen processing varies across cell
types with different endolysosomal pH ranges (6, 9). The highly
acidic environment within macrophages enables the efficient gen-
eration of peptides suitable for loading on MHC-II but results in
the loss of many potentially antigenic epitopes due to the harsh
processing conditions. In contrast, the endosomal pH is much
more strictly buffered within DC and generally remains in a much
more neutral range due to the alkalinizing actions of the NADPH
oxidase NOX2, which is recruited to phagosomal and endoso-
mal membranes (10). Thus, a different set of MHC-II-compatible
peptides emerges from antigen processing in different cell types.
Cross-presentation, the loading of exogenously derived anti-
gens onto MHC-I, is highly cell type-specific and has so far only
been documented to occur efficiently in DC. Given that epitopes
suitable for loading onto MHC-I are more susceptible to degra-
dation than MHC-II-compatible epitopes, the milder processing
conditions within DC are thought to provide the ideal environ-
ment for their generation (10–12). Subsequent to cell uptake by
endocytosis or phagocytosis, exogenous antigens within DC are
exposed to a near neutral endosomal/phagosomal pH resulting
from an incomplete assembly of the vacuolar (V)-ATPase on
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vesicle membranes as well as the Rac2 and Rab27a-dependent
recruitment of NOX2 (10, 11, 13). The generation of reactive
oxygen species (ROS) by NOX2 and subsequent consumption of
protons in the compartment results in a near neutral pH. Addi-
tionally, proteasomal recruitment of lysosomal proteases has been
shown to be lower in DC compared to macrophages (14). Such
mild conditions alone, however, cannot produce peptides suitable
for MHC-I loading and a critical step in cross-presentation is the
retro-translocation of antigen out of the endosomal compartment
and into the cytosol where it is processed by the proteasome in a
manner akin to endogenous proteins (15). The precise mecha-
nism for this retro-translocation is not known but the process of
ER-associated degradation (ERAD) and, specifically, the actions of
the Sec61 retrotranslocon have been implicated in the process (15,
16). The peptides generated by proteasomal processing are then
imported into the ER, where the majority of MHC-I is loaded
with peptide via the actions of TAP (15). Further peptide trim-
ming within the ER is mediated by ER aminopeptidases (ERAPs)
before nascent MHC-I molecules are loaded with the final epi-
tope assisted by chaperones such as calnexin and calreticulin (17).
While the involvement of the proteasome and ER machinery in
cross-presentation is well accepted, it has been proposed that the
phagosome or endosome itself may form a self-sufficient cross-
presentation compartment that contains significant amounts of
ER-associated proteins (18, 19). These include Sec61, TAP, IRAP
(an N-terminal peptidase very similar to ERAPs), and MHC-I
itself (18–20). It is perhaps most likely that these pathways are
not mutually exclusive and that the specific route through which
a given antigen is processed depends upon numerous factors.
This raises the important principle that for both MHC-I and
MHC-II antigen processing, there exists a very tight link between
the generation of suitable epitopes for MHC loading and the
environment within the antigen processing compartments. Thus,
regulation of antigen processing is highly susceptible to cellu-
lar and antigen context. Exposure of APC to stimuli such as
TLR ligands, pro- or anti-inflammatory cytokines, or hormones
can exert significant impact upon the phagolysosomal process-
ing efficiency by varying the pH, protease expression, endosomal
maturation processes, or signaling cascades initiated upon antigen
internalization (21–25).
RECEPTOR-MEDIATED ANTIGEN UPTAKE
The means by which an antigen is internalized is known to signifi-
cantly impact its intracellular handling by the cell. Many receptors,
particularly PRR, have been identified that promote antigen pre-
sentation either by increasing the rate of antigen uptake by other
cell surface receptors or by initiating signaling pathways, which
influence antigen handling once they are internalized. Impor-
tantly, different receptors can exert different effects on MHC-II
and MHC-I antigen presentation and this has been linked to
the routing of antigen to different compartments by the various
receptors. Thus, whereas internalization of an antigen by scav-
enger receptors enhances MHC-II loading and the activation of
CD4+ T cells, antigen uptake via the MR promotes MHC-I load-
ing and CD8+ T cell activation, likely by enhancing antigen export
to the cytosol (26–28). In contrast, C-type lectin receptors such as
CLEC9, Dectin-1, and DEC-205 (lymphocyte antigen 75), which
are expressed on macrophages and DC, promotes antigen pre-
sentation via both MHC-I and MHC-II (29–33). Indeed, many
studies have attempted to target antigen to these various receptors
in order to stimulate directed antigen presentation and gener-
ate enhanced antigen-targeted immune responses. The strategy
most commonly employed in these experiments has been to either
conjugate antigen or to fuse antigen with a receptor-specific mon-
oclonal antibody (32, 34, 35). Thus, while each of these strategies
has been shown to effectively enhance antigen-specific immune
responses, it cannot be excluded that such responses were partially
mediated by binding of the Fc portion of the targeting antibody
to FcγR, which would also enhance antigen presentation (36–38).
CLASSICAL Fcγ RECEPTORS
Cell surface expression of IgG binding receptors is a common fea-
ture of APC that allows them to react with high sensitivity to both
monomeric IgG and antigen-containing IgG IC. The family of
classical FcγR consists of several members with differential bind-
ing affinities and signaling capabilities, which transmit a diverse
range of responses upon ligation and thereby form a highly tunable
system for the regulation of immune responses.
Broadly, FcγR can be separated into activating and inhibit-
ing receptors, all of which likely arose from a series of gene
deletion/duplication and inter-gene recombination events (39).
In humans, activating receptors include hFcγRI, hFcγRIIA,
hFcγRIIC, hFcγRIIIA, and hFcγRIIIB, whereas in mice these
include mFcγRI, mFcγRIII, and mFcγRIV (37, 38). Activation by
these receptors is mediated by an immunoreceptor tyrosine-based
activation motif (ITAM) that is located either directly in the cyto-
plasmic tail of the receptor, in the case of FcγRII homologs, or in
the tail of the Fc receptor commonγ-chain (FCER1G), which asso-
ciates tightly with the cytoplasmic tails of FcγRI, hFcγRIIIA, and
mFcγRIV. Ligand binding induces phosphorylation of the ITAM
motifs by proto-oncogene tyrosine-protein kinase Src (SRC) fam-
ily kinases, which, in turn, trigger the recruitment and docking of
spleen tyrosine kinase (SYK) via its two SRC homology 2 (SH2)
domains. Subsequent autophosphorylation of SYK initiates a com-
plex web of intracellular signaling pathways including activation of
the mitogen-activated protein kinase (MAPK), phosphoinositide
3-kinase (PI-3K), and protein kinase C (PKC) cascades (40–42).
Inhibitory FcγRs include FcγRIIB orthologs in both mouse and
human systems, which possess an immunoreceptor tyrosine-based
inhibitory motif (ITIM) in their cytoplasmic tails. Upon ligand
binding, ITIM phosphorylation induces the recruitment of phos-
phatases such as SHIP-1 [inositol polyphosphate-5-phosphatase
(INPP5D)], which drive subsequent immunosuppression (37, 43).
Numerous polymorphisms, splice variants, and copy number vari-
ations for FcγR family members have been documented in both
humans and mice, many of which were shown to alter either ligand
binding, downstream signaling or be associated as risk factors for
human disease (44–46).
Importantly, the range of ligand binding affinities varies widely
across FcγR family members. In humans, FcγRI has the highest
affinity for monomeric IgG1, the lowest for monomeric IgG2, and
intermediate affinity for IgG3 and IgG4. Given this high affin-
ity for monomeric IgG, it is widely believed that most FcγRI is
saturated at steady state in the presence of physiological serum
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IgG concentrations (47). FcγRII and FcγRIII variants exhibit rela-
tively poor binding for monomeric IgG but a much higher binding
for multimeric IgG, such as is found in IgG IC, due to the ability
of such multivalent ligands to crosslink surface receptors. Further-
more, it is increasingly being appreciated that expression of FcγR
varies widely across types of APC. Whereas transcript analysis
has revealed that monocytes, macrophages, and monocyte-derived
DC (moDC) from mice express relatively high levels of all FcγR,
expression in DC subsets is considerably lower (38). Both XCR1+
and CD172α+ conventional DC (cDC) as well as plasmacytoid
DC (pDC) predominantly express FcγRIIA and FcγRIIB tran-
scripts with lower levels of expression of other FcγR. Indeed, three
groups have recently identified expression of FcγRI as a highly
sensitive marker for the differentiation of moDC from cDC (48–
52). These differences in affinity for IgG of different subclasses and
valencies as well as differential distribution of receptor expression
across APC types have important implications for the fine tuning
of immune regulation, as will be discussed below.
Internalization by FcγR has clearly been shown to increase the
ability of APC to present antigen contained within an IgG IC and
thus to stimulate CD4+ and CD8+ T cell responses (36, 53–57).
FcγR ligation by IgG leads to uptake of bound ligands by either
clathrin-dependent receptor-mediated endocytosis, if the ligand is
a small IgG IC, or by actin- and PI-3K-dependent phagocytosis, if
the ligand is a large IgG IC (58). FcγR-mediated internalization,
which is dependent on the common γ-chain, directs IgG IC into
an intracellular pathway that is conducive to antigen presentation
while simultaneously inducing maturation of the internalizing DC
(56, 59). Importantly, however, FcγR binding to IgG occurs at neu-
tral pH such as is found at the cell surface, but not in the acidic
pH range that is found in the endolysosomal system (60). FcγRs
are thus unable to bind their cargo intracellularly and such that
they release it in the acidifying endosomes soon after internaliza-
tion. Given the inability of FcγR to directly route IgG IC through
specific antigen processing compartments, it was thus unclear for
an extended period of time whether the contribution of FcγR to
enhanced antigen presentation was simply the result of increased
antigen uptake, of signaling pathways initiated by IgG IC-mediated
FcγR cross-linking or by an unidentified mechanism.
FcRn: AN INTRACELLULAR IgG BINDING RECEPTOR
The discovery of an intracellular IgG binding receptor distrib-
uted throughout the endolysosomal system within APC and which
exhibits specific binding only under acidic conditions presented
the possibility that IgG IC could be specifically trafficked toward
antigen processing compartments subsequent to FcγR-mediated
uptake.
Fc receptor was first identified in the intestinal epithelial cells
of neonatal rodents and thus came to be known as the neonatal
Fc receptor, FcRn (61). Indeed, FcRn remains best known for the
critical role it plays in transcytosis of IgG across intestinal epithe-
lial cells at mucosal barriers where it serves the important function
of delivering maternal IgG to neonatal rodents with undeveloped
immune systems (62–64). In the case of humans, such passive
acquisition of IgG in an FcRn-dependent manner occurs antena-
tally via the placenta (65, 66). However, discovery of FcRn in the
hepatocytes of adult rats was indicative that FcRn function was
not limited to the neonatal system and this was later substanti-
ated by the documentation of FcRn expression in adult human
intestinal epithelial cells (64, 67). Indeed, the other well-known
role for FcRn, protecting its serum ligands (IgG and albumin)
from catabolism via recycling, is an important process ongoing
throughout life (68, 69). Lifelong FcRn expression has now been
documented in a wide range of parenchymal cells in various tissues
including intestinal epithelial cells, airway epithelial cells, placental
syncytiotrophoblasts, hepatocytes, and endothelial cells in species
ranging from humans to rodents to camels (66, 67, 70–72). Crit-
ically, discovery of high level FcRn expression in hematopoietic
cells such as B cells, macrophages, and DC raised the possibility
that FcRn could be directly involved in the presentation of IgG-
complexed antigens to T cells, which themselves do not express
FcRn (73, 74).
Several key features of FcRn biology render it an ideal can-
didate molecule for participation in IgG IC antigen presentation
(Figure 1). FcRn, which is encoded by the Fcgrt gene, is an MHC-I
related molecule that associates directly with the β2-microglobulin
chain that enables its proper assembly and stability (75). FcRn is
located primarily intracellularly within the endolysosomal system
of APC and less so on the cell surface where it could theoretically
compete for IgG binding with FcγR (76). The critical binding site
for FcRn on the IgG Fc region involves the I253, H310, and H435
residues within the CH2:CH3 domains of IgG Fc and is distinct
from where FcγR binding to IgG occurs (77–84). In contrast to
FcγRs, binding is entirely independent of IgG glycosylation. Thus,
the simultaneous ligation of an IgG molecule by both classes of
receptor would be possible. FcRn binds IgG with very high affinity
of approximately 10 mM in a 2:1 stoichiometric ratio such that
binding of multimeric IgG IC would be expected to result in sig-
nificant cross-linking of FcRn (85–87). Perhaps most importantly
for the purposes of antigen presentation, binding of FcRn to IgG
occurs in the acidic pH range of 4.5–6.5 due to protonation of
the two critical histidine residues under low pH conditions and
the stabilization of the resulting salt bridges with acidic residues
in FcRn by a neighboring isoleucine residue (88, 89). These pHs
correspond to the pH range that is found across various compart-
ments of the endolysosomal system, thereby enabling direct high
affinity binding of FcRn to its ligand throughout the compart-
ments where the processing for antigen presentation is known to
occur (6, 90). Furthermore, FcRn is known to bind and actively
traffic monomeric IgG across polarized epithelial cells and within
endothelial cells, thereby establishing a direct precedent for its
ability to engage in endosomal IgG routing and consistent with
a dileucine motif in its cytoplasmic tail (91–94). FcRn thus pos-
sesses ideal characteristics enabling it to function downstream of
cell surface FcγR in facilitating the processing of IgG-complexed
antigens for presentation on MHC molecules.
FcRn IN MHC-II ANTIGEN PRESENTATION
The first indication that FcRn might enhance antigen presenta-
tion on MHC-II came from a study that examined the transfer
of IgG-complexed ovalbumin (OVA) across the intestinal barrier
and the delivery of IgG IC to local DC in the lamina propria
and mesenteric lymph nodes (mLN) (95). Subsequent to oral
administration of fluorescently labeled IgG IC, fluorescent signal

























































Baker et al. The role of FcRn in antigen presentation
FIGURE 1 | FcRn within dendritic cells enables the presentation of
IgG-complexed antigens to CD4+ T cells and CD8+ T cells. Following IgG
opsonization of antigens from sources such as microbes or tumors, the
immune complexes (IgG IC) bind to FcγR on the surface of dendritic cells
(DC). This initiates receptor-mediated endocytosis, which delivers the IgG
into the endolysosomal system of compartments. As these vesicles
become more acidic during their maturation due to the recruitment of the
vacuolar ATPase (V-ATPase), IgG IC dissociate from FcγR and bind instead
to FcRn, which enables the subsequent trafficking of the IgG IC into antigen
processing pathways that promote the generation of epitopes compatible
with loading onto MHC class I and MHC class II. Machinery known to be
involved in the presentation of soluble antigens for MHC class I processing
and presentation, such as gp91-phox, Rab27, Sec61, TAP (transporter
associated with antigen processing), and the proteasome, are all
preferentially recruited to the IgG IC-containing intracellular vesicles upon
ligation of FcRn. Less information is available on the compartments
involved in FcRn-facilitated MHC class II restricted presentation and it
remains unknown whether this occurs within the same intracellular
compartment as MHC class I-restricted processing. Once at the surface,
these peptide loaded MHC molecules are then able to prime CD8+ and
CD4+ T cells, respectively. Furthermore, ligation of FcRn by IgG IC induces
the production of IL-12 by the DC. The secreted IL-12 acts upon the primed
CD4+ T cells to induce Th1 polarization and upon the CD8+ T cells to
promote activation and cytotoxicity. FcRn within DC thus contributes to the
activation of cell-mediated adaptive immune responses that contribute to
pathogen eradication and tumor protection.
was detected in cells of the intestinal lamina propria and CD11c+
cells of the mLN in mice expressing a human FcRn transgene (hFC-
GRT/hB2M/mFcgrt−/−) but not in mice deficient in expression of
FcRn (Fcgrt−/−). This result clearly indicated that efficient uptake
of IgG IC by mucosal DC occurs preferentially in FcRn-expressing
mice and is consistent with the demonstration that FcRn on neu-
trophils increases the rate of phagocytosis of IgG IC (96). Cocul-
ture of OVA-specific CD4+ T cells with CD11c+ cells isolated from
the mLN of mice fed OVA IgG IC induced T cell activation only
if the mice expressed FcRn. These data strongly indicated that DC
were capable of activating T cells in response to IgG IC but did not
conclusively show that FcRn’s locus of action was in the DC since
drastically less IgG IC would reach DC in Fcgrt−/− animals given
the inability of FcRn-deficient epithelium to transcytose lumenal
IgG IC. Similarly, the demonstration that FcRn contributes to
protection from the intestinal pathogen Citrobacter rodentium in
the presence of specific IgG and that proliferation of C. roden-
tium-specific CD4+ T cells in the mLN was only observed in mice
expressing an epithelial-specific FcRn transgene cannot be said to
indicate a direct role for FcRn in antigen presentation (97). Thus,
while these studies elegantly demonstrated the role of FcRn in
delivering lumenal IgG IC to the mucosal immune system and
thereby enabling monitoring of its contents, they do not conclu-
sively demonstrate a role for FcRn in the direct presentation of
antigen by APC.
Conclusive evidence supporting a direct role for FcRn in medi-
ating MHC-II antigen presentation was achieved in a study that
was the first to document that FcRn responds differentially to
monomeric IgG and multimeric IgG IC. Whereas monomeric IgG
is protected in the circulation by FcRn in both hematopoietic
and parenchymal cells, leading to profound hypogammaglobu-
linemia in Fcgrt−/− animals, multimeric IgG IC are much more
rapidly cleared from the circulation of wild type (WT) mice than
monomeric IgG (69, 76, 98). Importantly, bone marrow chimeras
in which WT mice were reconstituted with bone marrow cells from
either WT or Fcgrt−/− animals clearly indicated that hematopoi-
etic cells were responsible for the rapid loss of IgG IC from cir-
culation. This finding suggested that IgG IC were being degraded
within hematopoietic cells, a process that might lead to the gen-
eration of epitopes for loading onto MHC molecules. Indeed, DC
isolated from WT mice were able to efficiently prime CD4+ T
cells when they had been pre-incubated with IgG IC formed in
the presence of as little as 0.05µg/ml of OVA antigen. DC isolated
from Fcgrt−/− animals, in contrast, required antigen concentra-
tions nearly 1000-fold higher in order to induce equivalent CD4+
T cell activation, indicating that FcRn greatly enhances the ability
of DC to generate MHC-II compatible epitopes from IgG IC-
delivered antigens. These results were confirmed with the use of
IHH-IgG, a chimeric antibody molecule engineered to have ala-
nine substitutions in three Fc-domain residues critical for binding
to FcRn (I253A, H310A, and H435A) and thereby unable to bind
to FcRn while retaining FcγR binding affinity (99). WT DC incu-
bated with IHH-IgG IC failed to induce efficient CD4+ T cell
proliferation compared to those incubated with the non-mutated
parental IgG. Confocal microscopy on human moDC loaded with
fluorescently labeled IgG IC revealed strong colocalization with
FcRn within 5 min of IgG IC exposure. Furthermore, whereas IgG
IC were directed into a LAMP1+ compartment within 30 min,
IHH-IgG IC did not co-localize with LAMP1 and instead seemed
to disappear from the cell entirely in this time frame. Given that
LAMP1 is a well-known lysosomal marker, these data indicate that
FcRn functions to direct IgG IC into lysosomes, which is a com-
partment in which MHC-II compatible epitopes are known to be
efficiently generated (1). Together, these findings firmly establish
that FcRn in DC contributes directly to activation of CD4+ T cells
via a mechanism involving degradation of IgG-complexed antigen
in a manner, which generates epitopes compatible with MHC-II
loading.
Details of the mechanism by which FcRn promotes MHC-II
antigen presentation have not yet been fully elucidated; how-
ever, several studies have identified important components of the
process. Whereas FcRn enhanced antigen presentation in both

























































Baker et al. The role of FcRn in antigen presentation
bone marrow-derived macrophages (BMMC) and dendritic cells
(BMDC) following FcRn-mediated endocytosis, this effect was
lost in BMDC, but not BMMC, when the antigen was taken up
via phagocytosis (100). This was shown to be due to the failure
of phagocytosing BMDC to adequately acidify their phagosomes
subsequent to IgG IC internalization, which is a known charac-
teristic of DC but is non-permissive for FcRn–IgG binding (1,
101). In contrast, BMMC efficiently acidified both phagosomes
and endosomes thereby promoting binding of FcRn to its IgG
IC ligand. Sufficient acidification of the endocytic environment
is thus a key factor for FcRn-mediated MHC-II antigen presenta-
tion. Interestingly, FcRn has been found to interact directly with
the invariant chain (CD74) that is critical for assembly and traf-
ficking of MHC-II molecules and is upregulated by inflammatory
stimuli (1, 102). In fact, trafficking of FcRn into the late endosome
and lysosome of epithelial cells, macrophages, and DC was shown
to be entirely dependent upon its co-expression with the invariant
chain. In contrast, the cytoplasmic tail of FcRn itself played almost
no role in determining FcRn localization throughout these com-
partments since reconstitution of cells with a tailless FcRn mutant
had little impact on its endolysosomal distribution as long as the
invariant chain was also present in the cells. The relevant residues
for mediating FcRn trafficking were found to be two dileucine-
based motifs located in the endosomal sorting signal cytoplasmic
tail of the invariant chain (103). The interaction between FcRn and
the invariant chain was initiated in the ER and persisted through-
out the endosomal system. It thus appears that FcRn shares a very
similar intracellular sorting route to MHC-II whose endolysoso-
mal distribution has also been shown to depend on its association
with the invariant chain (104, 105). This is particularly interesting,
given the recent findings that phagosomes behave autonomously
in terms of cargo degradation and MHC-II antigen presentation
and that the resulting CD4+ T cell activation was significantly
accelerated when antigen was delivered in the form of an IgG
IC (106). Thus, the tight overlap between the trafficking of the
two molecules places FcRn in an ideal position to deliver IgG-
complexed antigens for loading onto proximal MHC-II molecules
subsequent to their processing by lysosomal proteases.
FcRn IN MHC-I ANTIGEN CROSS-PRESENTATION
Conclusive evidence that FcRn in DC contributes to CD4+ T
cell activation in response to IgG-complexed antigens raised
the likelihood that it might also mechanistically contribute to
the cross-presentation of antigens in IgG IC. Numerous studies
demonstrating that IgG IC efficiently deliver antigens into a cross-
presentation pathway strongly supported this hypothesis (56, 59,
107). Importantly, each of these studies identified FcγR as being
critical for initiating cross-presentation and, while endosome-to-
cytosol transport (59), proteasomal processing, and TAP1–TAP2
transport (56) were identified as important for FcγR-dependent
antigen processing, the intracellular routing of the IgG IC itself
was not investigated.
In contrast to MHC-II antigen presentation, which is car-
ried out by most types of APC, cross-presentation occurs selec-
tively within DC. Specifically, the majority of literature on cross-
presentation has identified the CD8+ DC subset in mice, or their
human BDCA-3+ DC counterparts, as being by far the most
competent cross-presenters compared to even other DC subsets
(108–110). Mechanistically, this has been explained by their non-
monocytic lineage, which confers a distinctly neutral endosomal
pH enabling preservation of antigenic integrity for the genera-
tion of intact epitopes conducive to MHC-I loading (6, 10, 11,
101). A caveat to these findings on the competency of DC sub-
sets for cross-presentation is that most studies have examined the
process of cross-presentation as it pertains to soluble protein anti-
gen. The one study having examined cross-presentation of IgG
IC by different DC subsets reported that CD8− DC were capa-
ble of cross-presenting IgG IC at a similar magnitude to their
CD8+ counterparts but that there was an absolute requirement
for expression of functional FcγR only on the CD8− DC (107).
Initial studies of the ability of FcRn to mediate cross-
presentation of IgG-complexed antigen were carried out in
CD8+CD11b− and CD8−CD11b+ DC over a wide range of anti-
gen concentrations. Whereas cross-presentation of antigen deliv-
ered as an IgG IC was not affected by FcRn in CD8+CD11b− DC,
cross-presentation of IgG-complexed antigens by CD8−CD11b+
DC was significantly impaired in the absence of FcRn (60).
CD8−CD11b+ DC expressing FcRn were able to activate a robust
CD8+ T cell response when exposed to antigen concentrations
100-fold lower than DC from Fcgrt−/− mice. Similar results were
seen when CD8−CD11b+DC were exposed to IHH-IgG IC, which
were no more effective at priming CD8+ T cells than soluble
antigen. Importantly, whereas CD8+CD11b− DC were found to
activate CD8+ T cells in response to the cross-presentation of
5–10µg/ml soluble antigen, as reported in the literature, FcRn
enabled CD8−CD11b+ DC to stimulate similar magnitudes of
CD8+ T cell activation in response to as little as 0.5µg/ml of IgG-
complexed antigen (10, 11, 60, 101, 111). In fact, at high antigen
concentrations or following prolonged incubation times where
soluble uptake of antigen is efficient, FcRn was not observed to
promote cross-presentation (100). Consistent with initial stud-
ies showing the importance of FcγR for cross-presentation of
IgG IC, FcγR were found to be critical for FcRn-mediated cross-
presentation by enabling the initial cell surface binding of IgG
IC and facilitating internalization of the complexes into FcRn-
containing endosomes or phagosomes. The physiological rele-
vance of this process was established by subsequent in vivo studies
demonstrating the importance of FcRn in establishing system-
wide immunity resulting from cross-priming and conferring pro-
tection from colorectal cancer (CRC) (112, 113). These data pro-
vided conclusive evidence that FcRn enables cross-presentation
of IgG-complexed antigens downstream of FcγR and that this is
a physiologically meaningful process, which is active in initiating
immune responses to low doses of antigen in the early stages of
infection.
The differential ability of FcRn to enable cross-presentation
in CD8−CD11b+ versus CD8+CD11b− DC was found to reflect
the known biology of these two DC subsets. Given that the IgG–
FcRn interaction requires an acidic pH, the neutral pH that
is present in endocytic compartments of CD8+CD11b− DC is
not conducive to strong ligand receptor interaction. In contrast,
the intermediate endosomal acidity level of CD8−CD11b+ DC
between that of macrophages and CD8+CD11b− DC provides an
ideal binding environment for FcRn binding to IgG IC (6, 9). The
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importance of acidification to FcRn-mediated cross-presentation
was shown by its inhibition in the presence of vacuolar ATPase
(V-ATPase) inhibitors and by the active enrichment of V-ATPase
on the phagosomal membranes of compartments in which FcRn
was crosslinked by IgG IC but not on those containing IHH-IgG
IC (60). Nonetheless, the process by which FcRn enables cross-
presentation employs much of the same molecular machinery
as does the cross-presentation of soluble antigen by CD8+ DC.
Specifically, FcRn ligation by IgG IC led to the selective enrichment
of the NOX2 component gp91-phox, the Sec61 retrotranslocator,
the TAP transporter, and the Rab27a GTPase to phagosomal mem-
branes. Furthermore, FcRn-mediated cross-presentation required
cytosolic export of antigen and proteasomal processing. In addi-
tion to directing IgG IC toward specialized antigen processing
mechanisms, which lead to the surface presentation of epitope-
loaded MHC-I, cross-linking of FcRn by IgG IC induced a sig-
naling cascade, resulting in enhanced secretion of the cytotoxicity
promoting cytokine IL-12, thereby providing an additional stimu-
lus to encourage activation of antigen-primed and specific CD8+
T cells (113). FcRn within CD8−CD11b+ DC thereby enables
cross-presentation of antigen within IgG IC via multiple mech-
anisms. Among others, these include trafficking of complexed
antigen into a processing pathway that promotes epitope conser-
vation but which is not the default pathway for soluble antigens in
CD8− DC.
Identification of FcRn as a necessary facilitator for IgG IC
cross-presentation provides an important intracellular mecha-
nistic explanation for numerous demonstrations of the ability
of IgG IC to activate CD8+ T cells. Similarly, existing studies
not having directly examined FcRn but having looked at IgG
IC-mediated cross-presentation can provide valuable informa-
tion about additional processes that are likely to be involved
in FcRn-mediated cross-presentation. The existence of an anti-
gen storage compartment that persists for a prolonged period
of time within IgG IC-loaded CD8− DC is not only consistent
with the slower phagosome-to-cytosol release kinetics observed
for FcRn-mediated antigen presentation but also suggests that the
stable binding of FcRn to IgG IC in the acidic endolysosomal
environment might contribute to creating a durable reservoir of
immunostimulatory antigen (60, 114). With respect to additional
DC subsets, pDC, which cross-present soluble antigen poorly, dis-
play significantly enhanced cross-presentation when antigens are
targeted to the surface FcγR in the form of IgG IC (22, 115).
Given the dependence of IgG IC cross-presentation on intracellu-
lar processing downstream of FcγR-mediated uptake, this finding
predicts a role for FcRn in the cross-presentation of IgG IC by
pDC. Furthermore, studies on human DC subsets have demon-
strated enhanced cross-presentation when antigen is delivered in
the form of an IgG complex, thus, indicating that FcRn’s abil-
ity to enhance CD8+ T cell activation via cross-priming extends
to human DC (22, 116). Direct proof of FcRn’s ability to enhance
MHC-I driven activation of CD8+ T cells and MHC-II driven acti-
vation of CD4+ T cells in humans will have significant therapeu-
tic implications based on the number of physiological processes
shown experimentally to be regulated by FcRn-mediated antigen
presentation.
PHYSIOLOGICAL SIGNIFICANCE OF FcRn-MEDIATED ANTIGEN
PRESENTATION
Fc receptor-mediated antigen presentation plays a significant role
in the regulation of physiological processes that contribute to
health and disease. Indeed, an important positive feedback loop
exists between FcRn-mediated MHC-II antigen presentation and
the production of IgG by B cells. Targeting antigen to DC is a
known mechanism to induce CD4+ T cell help, which is essential
for antibody responses (117). This process of driving T cell help
for promoting humoral immunity has been shown to be further
accelerated when antigen is delivered to DC in the form of an IgG
IC, which stimulates FcγR-mediated antigen uptake (118). That
this process is dependent on FcRn-mediated processing of the IgG
IC itself has been shown in a series of studies using an animal
model in which the bovine FcRn (bFcRn) has been overexpressed
in transgenic mice (119, 120). Immunization of bFcRn transgenic
mice, even using weakly immunogenic antigens, led to significantly
greater expansion of antigen-specific B cells and plasma cells com-
pared to immunization of WT mice, a finding that is consistent
with the binding of bFcRn to mouse IgG (119–122). Importantly,
not only was production of antigen-targeted antibody increased
in bFcRn overexpressing mice but significantly greater diversity in
the antibody repertoire was seen following immunization (119).
Given that increased antigen-specific antibody production can be
expected to lead to greater amounts of antigen presentation by
FcRn and thus feed back to even greater antibody synthesis, these
results demonstrate that FcRn contributes to shaping the produc-
tion and diversity of its own ligand and thus serves an important
role in both cellular and humoral immunity.
The end result of FcRn-mediated antigen presentation is often
a powerful pro-inflammatory response which can be either helpful
or harmful depending on the context. Opsonization of infectious
agents is a critical parameter in the eradication of many pathogens
and, while protection is partially attributable to antibody depen-
dent cellular cytotoxicity (ADCC), evidence indicates that FcRn-
mediated antigen presentation also plays a significant role. FcRn
has been directly implicated in protection from intestinal C. roden-
tium infection in a model in which CD4+ T cell activation and IgG
are critical parameters in successful pathogen clearance (97). Addi-
tionally, FcRn contributes to CD4+ and CD8+ T cell activation in
response to vaccination with IgG opsonized and inactivated Fran-
cisella tularensis (123, 124). Upon rechallenge with F. tularensis,
mice having been vaccinated with the opsonized microbes were
significantly more protected from this intracellular pathogen than
microbe alone controls. FcRn-mediated protection from infection
in response to IgG-complexed microbial antigens is not only lim-
ited to bacterial pathogens but also extends to viral infections such
as influenza, herpes simplex, and HIV model viruses (125–127).
Importantly, FcRn-mediated protection induced by vaccination
against these viruses was shown to result in the generation of
long-term memory T cell responses, thereby confirming a mecha-
nistic role for antigen presentation in the process (126). Critically,
this body of work has firmly established that T cell-mediated
protection against microbial and viral antigens that is initiated
by IgG-complexed antigen, depends upon the antigen presenta-
tion function of FcRn within DC. Thus, FcRn-mediated antigen
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presentation provides an intracellular mechanism that explains
the findings of many other studies documenting IgG IC-driven
protection from infection. Among other pathogens, targeting anti-
gen in the form of IgG IC toward FcγR has been shown to be
effective against human papilloma virus (HPV) and Salmonella
typhimurium via a mechanism which is most likely also depen-
dent upon FcRn following initial IgG IC uptake (128–131). The
antigen presentation function of FcRn in the context of invasive
pathogens is thus highly beneficial to the host, particularly since
its high sensitivity enables early immunological activation upon
infection.
The exquisite sensitivity of FcRn to enable the presentation of
small doses of antigen renders it a highly potent immunostim-
ulatory molecule. While this is advantageous in the context of a
foreign pathogen, FcRn-mediated antigen presentation can serve
to promote pathological inflammation in the context of autoim-
mune or allergic diseases. Antibody-enhanced cross-presentation
of self-antigens expressed by pancreatic β cells can drive the devel-
opment of CD8+ T cell-mediated autoimmune diabetes by break-
ing tolerance to endogenous molecules (132). Similarly, antigen
uptake by FcγR in DC has been shown to contribute to allergic
airway hyper-responsiveness and inflammation by driving CD4+
T cell activation via a mechanism that almost certainly involves
FcRn (133). Indeed, two additional studies have demonstrated a
direct effect for FcRn in the regulation of allergic airway inflam-
mation although they did not identify the cell compartment in
which FcRn was acting (134, 135). Perhaps the most conclusive
evidence for the ability of FcRn-mediated antigen presentation to
promote inflammation comes from studies conducted in the intes-
tine where FcRn has been shown to drive colitis in the presence of
anti-microbial IgG against the common microbial flagellin protein
(136). Whereas WT mice with high titers of anti-flagellin IgG due
to immunization with this ligand developed severe colitis upon
intestinal epithelial barrier breakage by dextran sodium sulfate
(DSS), Fcgrt−/− mice were largely protected from severe weight
loss and tissue damage in this model. Reciprocal bone marrow
chimeras in which serum IgG levels were normalized across all
experimental groups not only demonstrated that protection from
intestinal damage was not due to lower anti-flagellin IgG titers
in Fcgrt−/− animals but also identified the hematopoietic com-
partment as the source of FcRn-mediated inflammation. Further
study revealed that CD8−CD11b+ DC from the intestines of WT
colitic mice induced far greater CD8+ T cell activation in vitro
and in vivo compared to DC from Fcgrt−/− mice, directly indi-
cating the importance of FcRn in driving pro-inflammatory T cell
responses (60). In spite of the extensive tissue damage that results
from FcRn-mediated intestinal inflammation, however, WT mice
are significantly protected from the development of inflammation-
associated CRC in comparison to their Fcgrt−/− littermates in
whom the protection from FcRn-mediated inflammation trans-
lated into dampened anti-cancer immunity (113). Consistent with
the widely recognized importance of CD8+ T cells in conferring
anti-tumor immunity,depletion studies in conjunction with a DC-
specific deletion of FcRn conclusively identified FcRn-mediated
cross-presentation as the mechanism by which tumor protection
was enabled (98, 113). While numerous studies had previously
shown that vaccination strategies utilizing IgG-complexed tumor
antigens were far superior in driving tumor-protective immunity
compared to soluble tumor antigen, this was the first demon-
stration that FcRn in DC is an active and important part of the
endogenous anti-tumor immunosurveillance system (137).
LINGERING QUESTIONS IN FcRn-MEDIATED ANTIGEN
PRESENTATION
An important physiological role for FcRn-mediated antigen pre-
sentation has been conclusively demonstrated and many of the
key intracellular processes involved have been identified. Nonethe-
less, many valuable questions remain unanswered. How is FcRn-
mediated antigen presentation affected by additional stimuli such
as temporally or spatially proximal TLR-ligation within the IgG
IC-containing DC or the presence of mixed immune complexes
containing immunoglobulins of different subclasses of IgG or
immunoglobulin isotypes (138, 139)? How much impact do
characteristics of the IgG IC, such as ligand composition, IgG-
to-antigen ratios, and IgG IC size, have upon the immunologi-
cal outcome of FcRn-mediated antigen presentation (140–143)?
Are FcRn-trafficked IgG-complexed antigen processed within the
same intracellular compartment for MHC-I and MHC-II load-
ing or are IgG IC routed to distinct endocytic compartments for
each of these processes (106, 144–146)? How is FcRn trafficked
in different subsets or types of APCs and how does this relate to
the aforementioned questions? Addressing these and other queries
has important implications for the development of FcRn-targeted
therapeutics that could theoretically be tailored to trigger CD4+
T cells for an extracellular bacterial infection or CD8+ T cells for
tumor eradication. Our increasing understanding of the structural
details of the FcRn–IgG interaction open significant possibilities
for therapeutic development (80, 87) that can best be applied
and exploited by developing a complete understanding of the
mechanisms that govern FcRn-mediated antigen presentation.
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